RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Update

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 287 shares, a decline of 80.1% from the July 30th total of 1,444 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 113 shares, the days-to-cover ratio is presently 2.5 days.

RCN Pareto Strategic Allocation ETF Stock Performance

Shares of RCN Pareto Strategic Allocation ETF stock traded down $0.38 during trading hours on Friday, reaching $28.15. The company had a trading volume of 734 shares. The company has a market cap of $17.73 million, a price-to-earnings ratio of -29.32 and a beta of 1.07. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.58. The business has a fifty day moving average price of $27.75.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.